# SGLT2 Inhibitors in Geographic Atrophy

> **NCT07174687** · PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 70 (estimated)

## Conditions studied

- Retinal Degeneration
- Retinal Diseases
- Eye Diseases
- Geographic Atrophy
- Pathological Conditions, Anatomical

## Interventions

- **DRUG:** Dapagliflozin
- **OTHER:** Matching Placebo

## Key facts

- **NCT ID:** NCT07174687
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174687, "SGLT2 Inhibitors in Geographic Atrophy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07174687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*